Thalidomide, an antiangiogenic agent with clinical activity in cancer

S. S.W. Ng; M. Brown; W. D. Figg

doi:10.1016/S0753-3322(02)00177-4

Thalidomide, an antiangiogenic agent with clinical activity in cancer

S. S.W. Ng, M. Brown, W. D. Figg

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Abstract

Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article.

Original language	English
Pages (from-to)	194-199
Number of pages	6
Journal	Biomedicine and Pharmacotherapy
Volume	56
Issue number	4
DOIs	https://doi.org/10.1016/S0753-3322(02)00177-4
State	Published - 2002
Externally published	Yes

Keywords

HIV-infection
Thalidomide
VEGF
bFGF

Access to Document

10.1016/S0753-3322(02)00177-4

Cite this

@article{5bb7fcf4637347dbb8d248bc7cd0070e,

title = "Thalidomide, an antiangiogenic agent with clinical activity in cancer",

abstract = "Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article.",

keywords = "HIV-infection, Thalidomide, VEGF, bFGF",

author = "Ng, {S. S.W.} and M. Brown and Figg, {W. D.}",

year = "2002",

doi = "10.1016/S0753-3322(02)00177-4",

language = "English",

volume = "56",

pages = "194--199",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

number = "4",

}

TY - JOUR

T1 - Thalidomide, an antiangiogenic agent with clinical activity in cancer

AU - Ng, S. S.W.

AU - Brown, M.

AU - Figg, W. D.

PY - 2002

Y1 - 2002

N2 - Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article.

AB - Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article.

KW - HIV-infection

KW - Thalidomide

KW - VEGF

KW - bFGF

UR - http://www.scopus.com/inward/record.url?scp=0035985945&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(02)00177-4

DO - 10.1016/S0753-3322(02)00177-4

M3 - Review article

C2 - 12109812

AN - SCOPUS:0035985945

SN - 0753-3322

VL - 56

SP - 194

EP - 199

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

IS - 4

ER -

Thalidomide, an antiangiogenic agent with clinical activity in cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this